Overview of the new 2022 european society of cardiology guidelines on cardio-oncology
V.A. Sujayeva
The article presents the main provisions of the European Society of Cardiology (ESC) Guidelines on Cardio-Oncology, developed in collaboration with the European Hematology Association, the European Society for Therapeutic Radiology and Oncology, the International Society of Cardiac Oncology in 2022. This is the first ESC guidelines on cardio-oncology, with 272 new recommendations, making the document very informative and voluminous. In this regard, within the framework of this article, only some concepts, definitions and directions for managing cancer patients will be reflected. The main factors of cardiovascular risk, as well as existing approaches to their assessment in patients before the start of cancer therapy and at the stages of dynamic observation, will be considered in detail. Separately, cardiovascular risk stratification associated with cancer therapy in various categories of patients is given.
keywords: arterial hypertension, arrhythmias, biomarkers, cancer survivors, cardio-oncology, cardiotoxicity criteria, myocarditis, cancer, heart failure, cardiovascular risk, cardiovascular risk stratification, cancer therapy, electrocardiography, echocardiography.
for references: V.A. Sujayeva. Overview of the new 2022 european society of cardiology guidelines on cardio-oncology. Neotlozhnaya kardiologiya i kardiovaskulyarnye riski [Emergency cardiology and cardiovascular risks], 2022, vol. 6, no. 2, pp. 1582–1591.
1. Lyon A.R., López-Fernández T., Couch L.S., Asteggiano R., Aznar M.C., Bergler-Klein J., Boriani G., Cardinale D., Cordoba R., Cosyns B., Cutter D.J., de Azambuja E., de Boer R.A., Dent S.F., Farmakis D., Gevaert S.A., Gorog D.A., Herrmann J., Lenihan D., Moslehi J., Moura B., Salinger S.S., Stephens R., Suter T.M., Szmit S., Tamargo J., Thavendiranathan P., Tocchetti C.G., van der Meer P., van der Pal H.J.H. ESC Scientific Document Group. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS) [electronic resource] // European Heart Journal, 2022, ehac244. Available at: https://doi.org/10.1093/eurheartj/ehac244. (accessed 10.09.2022).
2. Di Lisi D., Madaudo C., Alagna G., Santoro M., Rossetto L., Siragusa S., Novo G. The new HFA/ICOS risk assessment tool to identify patients with chronic myeloid leukaemia at high risk of cardiotoxicity. ESC Heart Fail, 2022, vol. 9, no. 3, pp. 1914–1919. doi: 10.1002/ehf2.13897.
3. Visseren F.L.J., Mach F., Smulders Y.M., Carballo D., Koskinas K.C., Bäck M., Benetos A., Biffi A., Boavida J.M., Capodanno D., Cosyns B., Crawford C., Davos C.H., Desormais I., Di Angelantonio E., Franco O.H. et al. 2021 ESC Guidelines on cardiovascular disease pre-vention in clinical practice. Eur Heart J, 2021, vol. 42, no. 34, pp. 3227–3337.
4. Rossello X., Dorresteijn J.A., Janssen A., Lambrinou E., Scherrenberg M., Bonnefoy-Cudraz E., Cobain M,, Piepoli M.F., Visseren F.L., Dendale P. Risk prediction tools in cardiovascular disease prevention: a report from the ESC Prevention of CVD Programme led by the European Association of Preventive Cardiology (EAPC) in collaboration with the Acute Cardiovascular Care Association (ACCA) and the Association of Cardiovascular Nursing and Allied Professions (ACNAP). Eur J Prev Cardiol, 2019, vol. 26, no. 14, pp. 1534–1544. doi: 10.1177/2047487319846715.
5. Martín García A., Mitroi C., Mazón Ramos P., García Sanz R., Virizuela J.A., Arenas M., Egocheaga Cabello I., Albert D., Anguita Sánchez M., Arrarte Esteban V.I., Ayala de la Peña F., Bonanand Lozano C., Castro A. et al. Stratification and management of cardiovascular risk in cancer patients. A consensus document of the SEC, FEC, SEOM, SEOR, SEHH, SEMG, AEEMT, AEEC, and AECC. Rev Esp Cardiol (Engl Ed), 2021, vol. 74, no. 5, pp. 438–448. doi: 10.1016/j.rec.2020.11.020.
6. Caro-Codón J., López-Fernández T., Álvarez-Ortega C., Zamora Auñón P., Rodríguez I.R., Gómez Prieto P., Buño Soto A., Canales Albendea M., Albaladejo A., Mediavilla G., Feliu Batlle J., Rodríguez Fraga O., Martínez Monzonis A., González-Costello J. et al. Cardiovascular risk factors during cancer treatment. Prevalence and prognostic relevance: insights from the CARDIOTOX registry. Eur J Prev Cardiol, 2022, vol. 29, no. 6, pp. 859–868. doi: 10.1093/eurjpc/zwaa034.
7. Feijen E.A.M., Leisenring W.M., Stratton K.L., Ness K.K., van der Pal H.J.H., van Dalen E.C., Armstrong G.T., Aune G.J., Green D.M., Hudson M.M., Loonen J., Oeffinger K.C., Robison L.L., Yasui Y., Kremer L.C.M., Chow E.J. Derivation of anthracycline and anthraquinone equivalence ratios to doxorubicin for late-onset cardiotoxicity. JAMA Oncol, 2019, vol. 5, no. 6, pp. 864–871.
8. Pareek N., Cevallos J., Moliner P., Shah M., Tan L.L., Chambers V., Baksi A.J., Khattar R.S., Sharma R., Rosen S.D., Lyon A.R. Activity and outcomes of a cardio-oncology service in the United Kingdom–a five-year experience. Eur J Heart Fail, 2018, vol. 20, no. 12, pp. 1721–1731. doi: 10.1002/ejhf.1292.
9. Lyon A.R., Dent S., Stanway S., Earl H., Brezden-Masley C., Cohen-Solal A., Tocchetti C.G., Moslehi J.J., Groarke J.D., Bergler-Klein J., Khoo V., Tan L.L., Anker M.S., von Haehling S., Maack C., Pudil R., Barac A., Thavendiranathan P., Ky B. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society. Eur J Heart Fail, 2020, vol. 22, no. 11, pp. 1945–1960. doi: 10.1002/ejhf.1920.
10. Libby P., Sidlow R., Lin A.E., Gupta D., Jones L.W., Moslehi J., Zeiher A., Jaiswal S., Schulz C., Blankstein R., Bolton K.L., Steensma D., Levine R.L., Ebert B.L. Clonal hematopoiesis: crossroads of aging, cardiovascular disease, and cancer: JACC review topic of the week. J Am Coll Cardiol, 2019, vol. 74, no. 4, pp. 567–577.
11. Garcia-Pavia P., Kim Y., Restrepo-Cordoba M.A., Lunde I.G., Wakimoto H., Smith A.M., Toepfer C.N., Getz K., Gorham J., Patel P., Ito K., Willcox J.A., Arany Z., Li J., Owens A.T., Govind R., Nuñez B., Mazaika E., Bayes-Genis A., Walsh R. et al. Genetic variants associated with cancer therapy-induced cardiomyopathy. Circulation, 2019, vol. 140, no. 1, pp. 31–41. doi: 10.1161/CIRCULATIONAHA.118.037934.
12. Bhatia S. Genetics of anthracycline cardiomyopathy in cancer survivors. JACC CardioOncology, 2020, vol. 2, no. 4, pp. 539–552.
13. Zamorano J.L., Gottfridsson C., Asteggiano R., Atar D., Badimon L., Bax J.J., Cardinale D., Cardone A., Feijen E.A.M., Ferdinandy P., López-Fernández T., Gale C.P., Maduro J.H., Moslehi J., Omland T., Plana Gomez J.C., Scott J., Suter T.M., Minotti G. The cancer patient and cardiology. Eur J Heart Fail, 2020, vol. 22, no. 12, pp. 2290–2309.
